Research programme: urotensin-II receptor antagonists - GlaxoSmithKline
Alternative Names: SB328872; SB436811; SB657510Latest Information Update: 19 Apr 2011
At a glance
- Originator GlaxoSmithKline
- Class Pyrrolidines; Sulfonamides
- Mechanism of Action Urotensin II antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atherosclerosis; Diabetes mellitus; Heart failure; Hypertension
Most Recent Events
- 03 Sep 2008 Final pharmacodynamics data from a preclinical trial in Pressure-overload hypertrophy presented at the Congress of the European Society of Cardiology (ESC-2008)
- 21 Aug 2006 Preclinical trials in Atherosclerosis in United Kingdom (unspecified route)
- 21 Aug 2006 Preclinical trials in Diabetes mellitus in United Kingdom (unspecified route)